GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: ZLTQ
Buy $39

Zeltiq Aesthetics Inc (NASDAQ: ZLTQ) reiterated to Buy with price target $39 by Maxim Group

Wednesday,  Jan 14, 2015  9:25 AM ET by Betsy O'Brien Harrison

Maxim Group reiterated Zeltiq Aesthetics Inc (NASDAQ: ZLTQ) to Buy with price
target $39. Previously Maxim Group reiterated Zeltiq Aesthetics Inc (NASDAQ: ZLTQ) to Buy with price target $33 on 10/29/2014, when the stock price was $25.23.

ZELTIQ Aesthetics, Inc. (ZELTIQ) is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product is the CoolSculpting System that reduces stubborn fat bulges. The Company generates revenues from capital sales of its CoolSculpting System and from procedure fees its physician customers pay for each CoolSculpting procedure they perform. As of March 31, 2011, it had an installed base of 346 and 475 CoolSculpting Systems worldwide and over 88,000 CoolSculpting procedures had been sold to its physician customers. The Company markets CoolSculpting to the dermatologists, plastic surgeons, and aesthetic specialists. As of March 31, 2011, ZELTIQ?s North American direct sales force consisted of 23 professionals, and over 88,000 CoolSculpting procedures were sold to ZELTIQ?s physician customers.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy